Skip to main content

FDA Asked to Treat Superbugs Like Rare Diseases


By Anna Yukhananov
WASHINGTON (Reuters) Mar 08 - The Infectious Diseases Society of America is proposing a new approach to the problem of drug-resistant bacteria: turn infections into a rare disease.
The group offered a plan on Thursday that would allow the U.S. Food and Drug Administration (FDA) to review certain kinds of antibiotics like it reviews "orphan" drugs for rare diseases, making it easier for companies to gain approval.
Misuse of medications and other factors have fueled the evolution of multi-drug resistant "superbugs" for which there are few treatment options.
MRSA -- methicillin-resistant Staphylococcus aureus -- alone is estimated to kill around 19,000 people every year in the United States.
Many drugmakers have turned away from what has become an unprofitable area of research, leaving few medicines to fight drug-resistant strains.
Today, only two large companies -- GlaxoSmithKline Plc and AstraZeneca Plc -- still have strong antibiotic research and development, compared to nearly 20 companies in 1990, according to the IDSA.
Congress passed the Orphan Drug Act in 1983 to deal with a similar problem: too few companies were investing in drugs to treat uncommon diseases, usually ones that affected fewer than 200,000 people in the United States.
The law offered companies tax credits, marketing rights and other incentives.
Robert Guidos, IDSA's vice president of public policy and government relations, said a similar program could work for antibiotics, where the unmet need is just as great, while investment has plummeted.
"This proposal creates a new mechanism, similar to the orphan drug act (for rare diseases)," he said. "It's a game-changer," Guidos said.
Under IDSA's Special Population Limited Medical Use framework, companies that want to develop new antibiotics can enroll fewer patients in clinical trials and often get a faster response from the FDA.
To get approval for the program, companies would have to target their antibiotics at specific strains of disease that have few treatment options.
Janet Woodcock, head of the FDA's drugs center, said the incidence of drug-resistant bacteria has reached "crisis proportions" in the United States, but the FDA was concerned new antibiotics could be overused.
"We need antibiotics to be used for life-threatening infections that lack medical treatments ... and not for your kid's ear infection," Woodcock said during a briefing with reporters.
The World Health Organization warned last year that misuse of antibiotics was so bad it could bring nations back to the time before major antibiotics were developed.
Woodcock said the FDA was exploring creating a special designation for drugs that have the potential for misuse -- such as antibiotics and obesity treatments -- but can also benefit a limited number of patients.
These drugs would have strict labels on who they are meant for, and pharmacists and doctors would have to know the regulations.
While the FDA has no power to regulate medical practice, Woodcock said she believed this special designation would give doctors enough information to use medicine appropriately.
The IDSA said it would also work with insurers and doctors to make sure any antibiotics approved through the pathway would go to the right patients. IDSA represents about 10,000 physicians and scientists that focus on infectious diseases.
The group planned to submit its proposal on antibiotics to Congress during a hearing on Thursday about a bill to renew FDA user fees, or the funds companies pay to the agency in exchange for faster review of drugs and devices.
Since the fees provide almost half of the FDA's funding, the bill often serves as a vehicle for broader FDA-related changes. The fees must be renewed every five years, with the current bill expiring in September.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more